Page 3 - Sanofi

France's Sanofi SA to buy US-based Principia Biopharma for $3.7 billion

The deal will strengthen Sanofi's research capabilities in areas such as autoimmune and allergic diseases, the companies said

Sanofi snags US biotech asset with $3.7 bn deal for Principia Biopharma

PARIS (Reuters) - Sanofi SA is to buy U.S.-based Principia Biopharma Inc for around $3.7 billion, the companies announced on Monday, marking the French healthcare company's latest acquisition in the biotech sector.

French group Sanofi to buy US firm Principia Biopharma for $3.7 billion

PARIS (Reuters) - French healthcare company Sanofi SA has agreed to buy U.S. company Principia Biopharma Inc for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and development (R&D) areas.

US inks $1.5 bn deal with Moderna for 100 mn doses of Covid-19 'vaccine'

The US government previously gave Moderna around $1 billion to fund its research efforts, bringing total US funding to around $2.5 billion

Sanofi under investigation on charges including manslaughter over Depakine

Sanofi Aventis France added it had respected all its obligations regarding information provided on Depakine

European Union in talks to secure Sanofi deal for coronavirus vaccine

Armed with an emergency fund of more than 2 billion euros (1.80 billion pounds), the European Commission wants to strike deals with up to six drug makers for their vaccines

US to pay Sanofi, GSK $2.1 bn for Covid-19 vaccine to cover 50 mn people

A Sanofi executive said the companies had not yet agreed with the US on a specific price for additional doses

US pledges up to $2.1 billion for Sanofi, GlaxoSmithKline Covid-19 vaccine

Glaxo shares traded 1.6 per cent higher in London, with Sanofi up 1.4 per cent in Paris

Sanofi lifts earnings view as Regeneron stake sale boosts second quarter

Sanofi is working on two of the more than 150 potential Covid-19 vaccines being developed across the world

World Coronavirus Dispatch: WHO stops trials of HCQ, HIV cocktail

Glaxo, Sanofi near $624 mn vaccine deal, Mexico deaths top 30,000, uneven recovery for Arab world and other pandemic-related news across the globe

Families struggle to import life-saving drugs as lockdown hits grey market

With no new stock coming in, both patients and grey market vendors started running out of vigabatrin

Second-generation Covid-19 vaccines are built for impact over speed

Some of the world's most prolific and experienced vaccine developers -- Sanofi, GlaxoSmithKline and Merck & Co - are among at least 100 challengers trailing the leaders

Sanofi eyes Covid-19 vaccine approval in early 2021; partners Translate Bio

Many drugmakers are racing to come up with a safe and effective vaccine that can be produced at large scale

Sanofi stops enrolling Covid-19 patients in hydroxychloroquine trials

The moves come after the World Health Organization paused its large trial of hydroxychloroquine, prompting several European governments to ban the use of the drug

Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares

Earlier this week, Regeneron had said it would repurchase about $5 billion of its shares directly from Sanofi, without altering their over-a-decade-long partnership

GlaxoSmithKline, Sanofi strike deal to develop coronavirus vaccine

The drugmakers said they expect to start clinical trials for the vaccine in the second half of this year.

Biocon, Mylan win patent case for insulin device against Sanofi in US

Development takes Biocon a step closer to commercialise its glargine biosimilar Semglee in America

Sanofi to sell surgical product unit Seprafilm to Baxter for $350 mn

The deal should close by the end of the first quarter of 2010, Baxter added in a statement confirming the purchase, which was reported earlier by Reuters

Novartis takes on Sanofi, Amgen with $9.7-bn takeover of heart drug maker

Novartis shares were seen up 0.2%, premarket indicators showed.

Unlocking trapped value: Sanofi mulls $30 bn consumer business spinoff

All businesses are undergoing thorough reviews at the moment, according to the Paris-based company.